Sandoz to move to permanent headquarters in central Basel in mid-2024
Sandoz AG, a global supplier of generic and biosimilar medicines, announced the location of its future permanent headquarters in central Basel.
The Sandoz AG headquarters plans to move to a landmark office building called Elsässertor, in the center of Basel, right by the Basel SBB train station. Sandoz expects to move from the Novartis Campus to its new headquarters in mid-2024.
The announcement confirms the Sandoz commitment to Basel following its proposed separation from Novartis in the second half of 2023.
[Read more: Novartis to separate Sandoz generics drug unit into standalone company]
Sandoz CEO Richard Saynor said, “I’m delighted to confirm that we will continue to call Basel home. This is an important milestone on our way to becoming an independent company. Our planned location in the heart of the city will allow us to create a working environment that meets our business needs and reflects our identity, culture and values. Basel is a global center for the life sciences industry, attracting an unrivalled pool of talent and experience that will help us to grow further and achieve our ambition of being the sustainable global leader in generics and biosimilars.”
The planned new workspace will be designed to enable closer collaboration and teamwork across the organization. The move into the new office building will not impact the management of the Sandoz global business, the company said.
[Read more: Novartis' Sandoz generic drugs unit attracts attention]
Sandoz Pharmaceuticals AG, the local Swiss affiliate, and Sandoz Group AG, the entity planned to be listed on the Swiss SIX stock exchange, remain based in Rotkreuz, Switzerland.
In August 2022, Novartis announced its intention to separate Sandoz, its off-patent medicines division, via a 100% spin-off. The proposed spin-off is due to complete in the second half of 2023 and would see Sandoz listed on the SIX Swiss exchange.